ALFA Finder| Revenue growth | 15% YoY growth to 304 Cr in Q1 FY27. |
|---|---|
| Margins | Gross margin improved 3% points YoY to 33%. |
| Demand visibility | Cyclical demand in regulated markets; winter season expected to be better. |
| Management confidence | Cautiously optimistic; focusing on execution and cost discipline. |
Growth
Revenue grew 15% YoY to 304 Cr; EBITDA improved significantly to 25 Cr from 10 Cr YoY.
Outlook
Commissioning of 7-ACA and Cefiderocol projects by FY27; targeting high utilization in first year.
Risks
Industry overcapacity, cut-throat competition in non-regulated markets, and execution risks in large-scale fermentation projects like 7-ACA.
Last quarter's promises, checked
Delivered
- Targeted 10-15% base business growth → delivered 15% (= BEAT)
- Guided 12% EBITDA margin for base business → delivered 12.3% (= BEAT)
- Targeted Q1 FY27 recovery after FY26 pressure → delivered 304 Cr revenue (= BEAT)
Partly delivered
- 7-ACA project execution race against time → on track for FY27 commissioning (= PARTIAL)
Missed
- Targeted signing one Enmetazobactam deal by June 2026 → delivered 0 signed deals (= MISS)
Earnings Call Transcript filed with NSE, NSE: ORCHPHARMA. Summary written with AI assistance from the document.
Orchid Pharma Ltd: key numbers
- Share price
- ₹877.00
- Market cap
- ₹5,252 Cr
- Revenue (annual)
- ₹811.3 Cr
- Net profit (annual)
- ₹20.55 Cr
- P/E (TTM)
- 605.9×Sector 43.8×
- Promoter holding
- 74.45%+4.61% QoQ
- FII holding
- 0.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Orchid Pharma Ltd
All →Orchid Pharma Board Meeting Date
Orchid Pharma Ltd intimated that its board will meet on November 14, 2026 to consider Q2 and half-year unaudited results. The trading window stays closed until 48 hours after results declaration.
Orchid Pharma Partnership
Orchid Pharma entered a licensing and supply agreement with Laboratorio Libra for Exblifep across nine Latin American markets. The partnership is expected to represent a potential opportunity of about USD 80 million over 10 years.
Orchid Pharma Fund Raise of ₹600 Cr
Orchid Pharma's board approved an enabling resolution to raise funds of up to ₹600 Crore through equity or debt securities via various permissible modes.
- Value
- ₹600.0 Cr
Orchid Pharma Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Orchid Pharma Board Meeting Date
Orchid Pharma has scheduled a board meeting for October 20, 2026, to consider options for raising funds. The company will explore various suitable funding avenues.
Orchid Pharma Other Announcement
Orchid Pharma Ltd has filed its quarterly Shareholding Pattern, providing a routine update on promoter and public shareholding as mandated by SEBI regulations.